This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
“The achievements of our newly promoted Vice Presidents reflect the great year that CRA had in 2025 and reinforce my optimism in our future,” said CRA...
The objective of this report, commissioned by the BeyondTheNose initiative organised and funded by GSK, was to assess the barriers in the policy environment...
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...
